Exosens stock soars nearly 10% and takes the lead in the SBF 120
The publication of new annual targets propels the Bordeaux-based optronic company to the top of the SBF 120 this Thursday morning. The surge occurs as the stock recovers its moving averages after several weeks of pressure, in a broadly stable European market.
Exosens leads the SBF 120 with a gain of nearly 10% driven by its targets revision
Exosens climbs 9.84% to €59.70 during the session, posting the strongest gain in the SBF 120. This surge follows the upward revision of 2026 targets announced this morning: the group now expects revenue growth of approximately 20%, with a ceiling set at €570 million, and adjusted EBITDA growth of around 25%. Publication of the nine-month results is expected on October 27, just over a month away.
The CAC 40 gains 0.22% during the session, while the SBF 120 advances 0.21%, meaning the stock's outperformance is clear. Over the week, Exosens is already up 6.13%, but remains down 10.63% over a month, showing that today's rise partially catches up a recent decline without entirely erasing it.
A recovery above moving averages that strengthens the stock's technical setup
The session's surge repositions the stock technically above all of its moving averages. The price at €59.70 exceeds the 20-day MA at €57.86 (spread of +3.18%) and now sits near the 50-day MA at €59.43, with a spread of only +0.45%. It also breaks through the 200-day MA at €58.85, with a spread of +1.44%.
This triple recovery is noteworthy: just days ago, the stock had fallen back below all these levels, in a pressured configuration. The RSI at 37 remains in the lower zone, far from any overbought signal, leaving room before a potential technical resistance at €66.80. The next publication of nine-month results on October 27 will be the next information milestone on the group's trajectory.
